Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H19FN4O4.ClH |
| Molecular Weight | 398.817 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCN(CC1)C2=C3OCN(C)N4C=C(C(O)=O)C(=O)C(C=C2F)=C34
InChI
InChIKey=OCRYFLKYXNBUEY-UHFFFAOYSA-N
InChI=1S/C17H19FN4O4.ClH/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25;/h7-8H,3-6,9H2,1-2H3,(H,24,25);1H
DescriptionCurator's Comment: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05196313-2371-45ad-a6fb-6269f8ef94c5
Curator's Comment: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05196313-2371-45ad-a6fb-6269f8ef94c5
Marbofloxacin is an anti-bacterial veterinary medication which is approved by FDA and EMEA for the treatment of bacterial diseases in dogs and cats. The drug exerts its action by inhibiting bacterial DNA gyrase.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2311224 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Zeniquin Approved UseZeniquin (marbofloxacin) tablets are indicated for the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. Launch Date1999 |
|||
| Curative | Zeniquin Approved UseZeniquin (marbofloxacin) tablets are indicated for the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. Launch Date1999 |
|||
| Curative | Zeniquin Approved UseZeniquin (marbofloxacin) tablets are indicated for the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. Launch Date1999 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The disposition of marbofloxacin in Eurasian buzzards (Buteo buteo) after intravenous administration. | 2001 Apr |
|
| Pharmacokinetic behavior of marbofloxacin after intravenous and intramuscular administrations in adult goats. | 2001 Dec |
|
| Activity and postantibiotic effect of marbofloxacin, enrofloxacin, difloxacin and ciprofloxacin against feline Bordetella bronchiseptica isolates. | 2001 Jul 3 |
|
| A field comparison of the efficacy and tolerance of marbofloxacin in the treatment of bovine respiratory disease. | 2001 Oct |
|
| Multiresidue determination of (fluoro)quinolone antibiotics in swine kidney using liquid chromatography-tandem mass spectrometry. | 2002 Apr 5 |
|
| Pharmacokinetics of marbofloxacin in mature horses after single intravenous and intramuscular administration. | 2002 Jul |
|
| In vitro sensitivity of Hungarian Actinobaculum suis strains to selected antimicrobials. | 2003 |
|
| In vitro susceptibility of Arcobacter butzleri and Arcobacter cryaerophilus to different antimicrobial agents. | 2003 May |
|
| Antibiotic susceptibilities of recent isolates of Mycoplasma bovis in Belgium. | 2003 Oct 4 |
|
| Multiresidue determination of fluoroquinolones in milk by column liquid chromatography with fluorescence and ultraviolet absorbance detection. | 2004 Apr 23 |
|
| A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets. | 2004 Dec |
|
| Treatment of canine pyoderma with ibafloxacin and marbofloxacin--fluoroquinolones with different pharmacokinetic profiles. | 2004 Jun |
|
| Multiresidue method for simultaneous determination of ten quinolone antibacterial residues in multimatrix/multispecies animal tissues by liquid chromatography with fluorescence detection: single laboratory validation study. | 2005 Jul-Aug |
|
| A comparative study of two antimicrobial/anti-inflammatory formulations in the treatment of canine otitis externa. | 2005 Oct |
|
| Inclusion of marbofloxacin in PMMA orthopaedic cement: an in vitro experimental study. | 2006 |
|
| Simultaneous determination of (fluoro)quinolone antibiotics in kidney, marine products, eggs, and muscle by enzyme-linked immunosorbent assay (ELISA). | 2006 Apr 19 |
|
| Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves. | 2006 Dec |
|
| Clinical efficacy of intravenous administration of marbofloxacin in a Staphylococcus aureus infection in tissue cages in ponies. | 2006 Dec |
|
| Determination of fluoroquinolones in milk samples by postcolumn derivatization liquid chromatography with luminescence detection. | 2006 Dec 27 |
|
| Pharmacokinetics of marbofloxacin in blue and gold macaws (Ara ararauna). | 2006 Jun |
|
| Comparison of faecal and optimal growth conditions on in vitro pharmacodynamic activity of marbofloxacin against Escherichia coli. | 2006 Jun |
|
| Epidemiology and susceptibility of pathogenic bacteria responsible for upper respiratory tract infections in pet rabbits. | 2006 Jun 15 |
|
| Multiresidue method for the determination of quinolone antibiotics in bovine raw milk by capillary electrophoresis-tandem mass spectrometry. | 2006 Nov 15 |
|
| Effect of chronic FIV infection, and efficacy of marbofloxacin treatment, on Mycoplasma haemofelis infection. | 2006 Oct 31 |
|
| In vitro antimicrobial activity of marbofloxacin and enrofloxacin against bacterial strains isolated from companion animals. | 2007 Jun |
|
| Comparative pharmacokinetics of marbofloxacin in healthy and Mannheimia haemolytica infected calves. | 2007 Jun |
|
| Multiresidue method for simultaneous determination of quinolone antibacterials in pig kidney samples by liquid chromatography with fluorescence detection. | 2007 Nov 15 |
|
| Pharmacokinetic behavior and pharmacokinetic/pharmacodynamic integration of marbofloxacin after subcutaneous administration in goats. | 2007 Sep |
|
| Intraocular pharmacokinetics of intravenously administered marbofloxacin in rabbits with experimentally induced acute endophthalmitis. | 2008 Mar |
|
| Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections. | 2008 Sep 18 |
|
| Fully automatic sample treatment by integration of microextraction by packed sorbents into commercial capillary electrophoresis-mass spectrometry equipment: application to the determination of fluoroquinolones in urine. | 2009 Apr 15 |
Patents
Sample Use Guides
1.25 mg per pound (/lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.
Route of Administration:
Other
MIC50 values of marbofloxacin against pathogens isolated from skin, soft tissue and urinary tract infections in dogs were: Staphylococcus intermedius - 0.25 ug/ml, Escherichia coli - 0.03 ug/ml, Proteus mirabilis - 0.06 ug/ml, Beta-hemolytic Streptococcus, (not Group A or Group B) - 1 ug/ml, Streptococcus, Group D enterococcus - 1 ug/ml, Pasteurella multocida - 0.015 ug/ml, Staphylococcus aureus - 0.25 ug/ml, Enterococcus faecalis - 2 ug/ml, Klebsiella pneumoniae - 0.06 ug/ml.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
115551-26-3
Created by
admin on Sat Dec 16 19:46:27 GMT 2023 , Edited by admin on Sat Dec 16 19:46:27 GMT 2023
|
PRIMARY | |||
|
14576609
Created by
admin on Sat Dec 16 19:46:27 GMT 2023 , Edited by admin on Sat Dec 16 19:46:27 GMT 2023
|
PRIMARY | |||
|
W3C3ZZ8R2D
Created by
admin on Sat Dec 16 19:46:27 GMT 2023 , Edited by admin on Sat Dec 16 19:46:27 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
